Dr Andrew Tutt
Director, Breakthrough Breast Cancer Research Unit, Kings College London
Highly skilled and deeply committed, Dr Andrew Tutt brings valuable insights to Breakthrough. He combines his role of directing a research unit with the position of Consultant Oncologist in the multidisciplinary Breast Unit at Guy’s and St Thomas’ NHS Foundation Trust.
Andrew qualified in medicine at Bristol University in 1990 and, after postgraduate training in General Medicine, trained in clinical oncology at the Royal Marsden Hospital. He then went to work with Professor Alan Ashworth at the Institute of Cancer Research on a Medical Research Council Research Training Fellowship. Here, Andrew worked on functions of the BRCA2 breast cancer predisposition gene and was awarded his PhD in 2002.
Working with Professor Ashworth, Andrew has developed a translational clinical programme which focuses on cancers associated with functional deficiencies in BRCA1 and BRCA2. He is also Chief Investigator for the Cancer Research UK and Breakthrough Breast Cancer BRCA Trial, the Triple-Negative Trial and the ICEBERG studies into a potential new drug. Known as olaparib (a PARP inhibitor), the drug is being developed for women with hereditary breast and ovarian cancer.
Dr Andrew TuttI have been involved with Breakthrough Breast Cancer for many years. It is an honour to lead a team in developing one of the charity’s new research units.
